| Name | Title | Contact Details |
|---|
MBI Solutions is a Dayton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Katon Partners is a Rye, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Wellnet Healthcare Group is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For over 33 years, AultCare has been an industry leader in a competitive health care market. Through innovative plan designs, superior customer service and a cost effective, high quality network, AultCare has continued to keep enrollees and clients satisfied while remaining committed to providing affordable health care options. Throughout the years, AultCare has grown to become a valuable asset to our community. AultCare keeps costs lower than other areas in Ohio through our effective, high quality network. Our margins are smaller than national plans because we have accountability to our local community of individuals and employers. During our 30 years as an organization, teamwork has been a steadfast theme and it continues to remain an integral principle in our culture of nearly 500 employees. The unity of our teamwork has allowed us to be at the forefront for offering efficient health care to our community. Additionally, our commitment to teamwork has helped us provide excellent customer service, quality, and cost effective health care planning, which is at the standard core of our philosophy. Superior customer service is also an integral part of our daily business interactions. Due to the complexity of the health care industry, questions from members and employers may arise. All of our employees strive to provide an extra, personalized touch through all member interactions, whether over the phone or in person. AultCare brings a value to health care that is unparalleled in the market. As we continue to evolve, AultCare will welcome your feedback, strive to maintain our position as a steadfast leader in the health care industry, and be proud to serve you.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.